We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Risk Factor Identified for Life-Threatening Disease in Premature Infants

By LabMedica International staff writers
Posted on 03 Feb 2014
Many premature infants suffer a life-threatening bowel infection called necrotizing enterocolitis (NEC), and a marker has been identified in those infants who are at risk for the infection.

Since thrombocytopenia and bowel ischemia are consistent findings in advanced NEC, two potential biomarkers, reticulated platelets (RP) and intestinal alkaline phosphatase (iAP), were investigated. More...


Scientists at Loyola University Medical Center (Maywood, IL, USA) prospectively enrolled 177 infants born at less than 32 weeks' gestation and who were less than 1,500 grams in weight, from 2009 to 2012. Blood samples were collected from these infants within 72 hours of birth and weekly for four weeks to measure reticulated platelets (RP) and intestinal alkaline phosphatase (iAP). The percentage of reticulated platelets was determined by flow cytometry and serum iAP levels were determined by gel electrophoresis.

Of the 177 infants, 15 (8.5%) developed NEC and of these, 93% had low RP levels and 60% had high iAP. Those infants with low RP levels were significantly more likely to develop NEC while those with high iAP showed a similar trend. The study found that infants who would go on to develop NEC had significantly higher iAP levels at week four. While classically NEC occurs at week three of life, feeds of infants in the neonatal intensive care unit are advanced slowly and typically not started until near the end of the first week. The later initiation of feeds in the preterm infants in the study might be a reflection of them being extremely low birthweight infants (birthweight less than 1,000 g) and unstable at birth, delaying the onset of enteral feeds.

The authors concluded that as NEC affects up to 10% of very low birthweight infants, an already vulnerable population, it is important to discover reliable tests to detect those infants in this subpopulation who are most at risk of developing NEC in order to work towards prevention. Currently, no one test exists that can predict NEC; however, the team’s study suggests that the findings of low reticulated platelets and a high iAP may be useful in identifying those preterm infants at risk of NEC. Jonathan Muraskas, MD, the senior author, said, “Decreased reticulated platelets serve as a sensitive indicator for NEC onset. Further research also may find that infants with elevated iAP levels may be at risk.” The study was published online in the November 2013 issue of the Journal of Pediatric Surgery.

Related Links:

Loyola University Medical Center



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Urine Analyzer
respons® UDS100
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Guardant Health has introduced new applications for Guardant360 Liquid, expanding the test’s capabilities for treatment selection in breast and lung cancers. (Photo courtesy of Guardant Health)

Liquid Biopsy Expands Insights Into Treatment Response and Tumor Alterations

Treatment selection in advanced breast and lung cancers can be challenging when traditional biomarkers are absent and genomic findings alone do not fully clarify which therapies may be effective.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: VITEK PRO combines microbial identification and antimicrobial susceptibility testing on a single platform to support routine microbiology workflows and antibiotic selection. (Photo courtesy of bioMérieux)

Automated Microbial Identification and Susceptibility System Gains FDA Clearance

Antimicrobial resistance (AMR) is a leading global public health threat, causing an estimated 1.27 million deaths annually. The growing challenge of diagnosing and treating resistant infections highlights... Read more

Pathology

view channel
AI: Artificial intelligence; CNN: Convolutional neural networks; ResNet: Residual neural network. (Xing-hua Gao from The First Hospital of China Medical University, China Image Source Link: https://www.ovid.com/jnls/cmj/fulltext/10.1097/cm9.0000000000004154~deep-learning-based-computational-pathology-technologies)

Review Highlights Progress and Validation Needs for AI in Digital Pathology

Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more

Industry

view channel
Image: The collaboration aims to expand access to the technology through a regulated clinical diagnostics pathway in Japan.

Partnership Aims to Bring Blood-Based Alzheimer’s Testing to Japan

Alzheimer’s disease remains a growing diagnostic challenge as populations age and cognitive impairment becomes more common. In Japan, government-supported estimates project that approximately 4.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.